Sei Investments Co. boosted its position in Apyx Medical Corporation (NASDAQ:APYX – Free Report) by 298.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 598,255 shares of the company’s stock after purchasing an additional 448,174 shares during the period. Sei Investments Co. owned about 1.43% of Apyx Medical worth $2,208,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of APYX. AIGH Capital Management LLC purchased a new stake in Apyx Medical in the fourth quarter worth $3,867,000. Nantahala Capital Management LLC lifted its position in shares of Apyx Medical by 19.1% during the 4th quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock valued at $13,909,000 after buying an additional 636,043 shares during the last quarter. Informed Momentum Co LLC bought a new position in shares of Apyx Medical during the 4th quarter worth $863,000. Huntleigh Advisors Inc. bought a new position in shares of Apyx Medical during the 4th quarter worth $827,000. Finally, 683 Capital Management LLC purchased a new stake in Apyx Medical in the 4th quarter worth about $436,000. 55.33% of the stock is owned by institutional investors.
Apyx Medical Price Performance
Shares of NASDAQ APYX opened at $4.05 on Friday. The company has a debt-to-equity ratio of 2.68, a quick ratio of 4.79 and a current ratio of 5.80. Apyx Medical Corporation has a fifty-two week low of $1.70 and a fifty-two week high of $5.08. The stock has a market cap of $169.74 million, a PE ratio of -20.25 and a beta of 1.39. The stock has a fifty day moving average of $4.24 and a 200-day moving average of $3.94.
Analyst Ratings Changes
APYX has been the topic of a number of research reports. Zacks Research upgraded Apyx Medical to a “hold” rating in a research note on Tuesday, July 14th. HC Wainwright assumed coverage on shares of Apyx Medical in a research note on Monday, July 13th. They issued a “buy” rating and a $7.00 target price for the company. Wall Street Zen lowered shares of Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.60.
Check Out Our Latest Stock Analysis on APYX
About Apyx Medical
Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.
Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.
Recommended Stories
- Five stocks we like better than Apyx Medical
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Want to see what other hedge funds are holding APYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apyx Medical Corporation (NASDAQ:APYX – Free Report).
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.
